Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson’s disease patients
Abstract Parkinson’s disease (PD) is the neurological disorder showing the greatest rise in prevalence from 1990 to 2016. Despite clinical definition criteria and a tremendous effort to develop objective biomarkers, precise diagnosis of PD is still unavailable at early stage. In recent years, an inc...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-02-01
|
| Series: | npj Parkinson's Disease |
| Online Access: | https://doi.org/10.1038/s41531-021-00274-8 |
| _version_ | 1797425399688331264 |
|---|---|
| author | Gaia Meoni Leonardo Tenori Sebastian Schade Cristina Licari Chiara Pirazzini Maria Giulia Bacalini Paolo Garagnani Paola Turano PROPAG-AGEING Consortium Claudia Trenkwalder Claudio Franceschi Brit Mollenhauer Claudio Luchinat |
| author_facet | Gaia Meoni Leonardo Tenori Sebastian Schade Cristina Licari Chiara Pirazzini Maria Giulia Bacalini Paolo Garagnani Paola Turano PROPAG-AGEING Consortium Claudia Trenkwalder Claudio Franceschi Brit Mollenhauer Claudio Luchinat |
| author_sort | Gaia Meoni |
| collection | DOAJ |
| description | Abstract Parkinson’s disease (PD) is the neurological disorder showing the greatest rise in prevalence from 1990 to 2016. Despite clinical definition criteria and a tremendous effort to develop objective biomarkers, precise diagnosis of PD is still unavailable at early stage. In recent years, an increasing number of studies have used omic methods to unveil the molecular basis of PD, providing a detailed characterization of potentially pathological alterations in various biological specimens. Metabolomics could provide useful insights to deepen our knowledge of PD aetiopathogenesis, to identify signatures that distinguish groups of patients and uncover responsive biomarkers of PD that may be significant in early detection and in tracking the disease progression and drug treatment efficacy. The present work is the first large metabolomic study based on nuclear magnetic resonance (NMR) with an independent validation cohort aiming at the serum characterization of de novo drug-naive PD patients. Here, NMR is applied to sera from large training and independent validation cohorts of German subjects. Multivariate and univariate approaches are used to infer metabolic differences that characterize the metabolite and the lipoprotein profiles of newly diagnosed de novo drug-naive PD patients also in relation to the biological sex of the subjects in the study, evidencing a more pronounced fingerprint of the pathology in male patients. The presence of a validation cohort allowed us to confirm altered levels of acetone and cholesterol in male PD patients. By comparing the metabolites and lipoproteins levels among de novo drug-naive PD patients, age- and sex-matched healthy controls, and a group of advanced PD patients, we detected several descriptors of stronger oxidative stress. |
| first_indexed | 2024-03-09T08:15:35Z |
| format | Article |
| id | doaj.art-4dfc44c55695429ba954556d3c28b093 |
| institution | Directory Open Access Journal |
| issn | 2373-8057 |
| language | English |
| last_indexed | 2024-03-09T08:15:35Z |
| publishDate | 2022-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Parkinson's Disease |
| spelling | doaj.art-4dfc44c55695429ba954556d3c28b0932023-12-02T22:23:58ZengNature Portfolionpj Parkinson's Disease2373-80572022-02-018111010.1038/s41531-021-00274-8Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson’s disease patientsGaia Meoni0Leonardo Tenori1Sebastian Schade2Cristina Licari3Chiara Pirazzini4Maria Giulia Bacalini5Paolo Garagnani6Paola Turano7PROPAG-AGEING ConsortiumClaudia Trenkwalder8Claudio Franceschi9Brit Mollenhauer10Claudio Luchinat11Magnetic Resonance Center (CERM) and Department of Chemistry “Ugo Schiff”, University of Florence, Sesto FiorentinoMagnetic Resonance Center (CERM) and Department of Chemistry “Ugo Schiff”, University of Florence, Sesto FiorentinoDepartment of Clinical Neurophysiology, University Medical Center GoettingenMagnetic Resonance Center (CERM) and Department of Chemistry “Ugo Schiff”, University of Florence, Sesto FiorentinoIRCCS Istituto delle Scienze Neurologiche di BolognaIRCCS Istituto delle Scienze Neurologiche di BolognaDepartment of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of BolognaMagnetic Resonance Center (CERM) and Department of Chemistry “Ugo Schiff”, University of Florence, Sesto FiorentinoUniversity Medical Center Goettingen, Department of Neurology and Paracelsus-Elena-KlinikDepartment of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of BolognaUniversity Medical Center Goettingen, Department of Neurology and Paracelsus-Elena-KlinikMagnetic Resonance Center (CERM) and Department of Chemistry “Ugo Schiff”, University of Florence, Sesto FiorentinoAbstract Parkinson’s disease (PD) is the neurological disorder showing the greatest rise in prevalence from 1990 to 2016. Despite clinical definition criteria and a tremendous effort to develop objective biomarkers, precise diagnosis of PD is still unavailable at early stage. In recent years, an increasing number of studies have used omic methods to unveil the molecular basis of PD, providing a detailed characterization of potentially pathological alterations in various biological specimens. Metabolomics could provide useful insights to deepen our knowledge of PD aetiopathogenesis, to identify signatures that distinguish groups of patients and uncover responsive biomarkers of PD that may be significant in early detection and in tracking the disease progression and drug treatment efficacy. The present work is the first large metabolomic study based on nuclear magnetic resonance (NMR) with an independent validation cohort aiming at the serum characterization of de novo drug-naive PD patients. Here, NMR is applied to sera from large training and independent validation cohorts of German subjects. Multivariate and univariate approaches are used to infer metabolic differences that characterize the metabolite and the lipoprotein profiles of newly diagnosed de novo drug-naive PD patients also in relation to the biological sex of the subjects in the study, evidencing a more pronounced fingerprint of the pathology in male patients. The presence of a validation cohort allowed us to confirm altered levels of acetone and cholesterol in male PD patients. By comparing the metabolites and lipoproteins levels among de novo drug-naive PD patients, age- and sex-matched healthy controls, and a group of advanced PD patients, we detected several descriptors of stronger oxidative stress.https://doi.org/10.1038/s41531-021-00274-8 |
| spellingShingle | Gaia Meoni Leonardo Tenori Sebastian Schade Cristina Licari Chiara Pirazzini Maria Giulia Bacalini Paolo Garagnani Paola Turano PROPAG-AGEING Consortium Claudia Trenkwalder Claudio Franceschi Brit Mollenhauer Claudio Luchinat Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson’s disease patients npj Parkinson's Disease |
| title | Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson’s disease patients |
| title_full | Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson’s disease patients |
| title_fullStr | Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson’s disease patients |
| title_full_unstemmed | Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson’s disease patients |
| title_short | Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson’s disease patients |
| title_sort | metabolite and lipoprotein profiles reveal sex related oxidative stress imbalance in de novo drug naive parkinson s disease patients |
| url | https://doi.org/10.1038/s41531-021-00274-8 |
| work_keys_str_mv | AT gaiameoni metaboliteandlipoproteinprofilesrevealsexrelatedoxidativestressimbalanceindenovodrugnaiveparkinsonsdiseasepatients AT leonardotenori metaboliteandlipoproteinprofilesrevealsexrelatedoxidativestressimbalanceindenovodrugnaiveparkinsonsdiseasepatients AT sebastianschade metaboliteandlipoproteinprofilesrevealsexrelatedoxidativestressimbalanceindenovodrugnaiveparkinsonsdiseasepatients AT cristinalicari metaboliteandlipoproteinprofilesrevealsexrelatedoxidativestressimbalanceindenovodrugnaiveparkinsonsdiseasepatients AT chiarapirazzini metaboliteandlipoproteinprofilesrevealsexrelatedoxidativestressimbalanceindenovodrugnaiveparkinsonsdiseasepatients AT mariagiuliabacalini metaboliteandlipoproteinprofilesrevealsexrelatedoxidativestressimbalanceindenovodrugnaiveparkinsonsdiseasepatients AT paologaragnani metaboliteandlipoproteinprofilesrevealsexrelatedoxidativestressimbalanceindenovodrugnaiveparkinsonsdiseasepatients AT paolaturano metaboliteandlipoproteinprofilesrevealsexrelatedoxidativestressimbalanceindenovodrugnaiveparkinsonsdiseasepatients AT propagageingconsortium metaboliteandlipoproteinprofilesrevealsexrelatedoxidativestressimbalanceindenovodrugnaiveparkinsonsdiseasepatients AT claudiatrenkwalder metaboliteandlipoproteinprofilesrevealsexrelatedoxidativestressimbalanceindenovodrugnaiveparkinsonsdiseasepatients AT claudiofranceschi metaboliteandlipoproteinprofilesrevealsexrelatedoxidativestressimbalanceindenovodrugnaiveparkinsonsdiseasepatients AT britmollenhauer metaboliteandlipoproteinprofilesrevealsexrelatedoxidativestressimbalanceindenovodrugnaiveparkinsonsdiseasepatients AT claudioluchinat metaboliteandlipoproteinprofilesrevealsexrelatedoxidativestressimbalanceindenovodrugnaiveparkinsonsdiseasepatients |